Business Context and Reporting Period
This Form 8-K is filed by Ra Medical Systems, Inc. (not Catheter Precision, Inc.) on October 29, 2019. The report addresses significant corporate governance events, including the termination of a senior executive and the conclusion of an Audit Committee investigation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial operational and governance events.
Material Changes and Events
- Executive Departure: On October 29, 2019, the Company terminated Melissa Burstein as Vice President, effective November 1, 2019. The termination was without "Cause" under her Change in Control and Severance Agreement.
- Severance and Equity: Ms. Burstein is eligible for severance compensation benefits per her agreement. Her existing equity incentive awards remain subject to their original terms.
- Audit Committee Investigation: On October 31, 2019, the Company announced the substantial completion of a previously announced Audit Committee investigation.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the implementation of remedial measures recommended by the Audit Committee and the review of previously issued financial statements. Key risks and contingencies include:
- Uncertainty regarding the promptness and thoroughness of implementing Audit Committee recommendations.
- Potential legal or regulatory actions related to the matters under investigation.
- Outcomes of further reviews of financial statements and internal controls by the Company or independent auditors.
- Impact of a recently announced change in product shelf life.
- Timing of the Company's atherectomy trial and future periodic reports.
Investor Verification Checklist
- Verify the terms of the severance agreement filed as Exhibit 10.9 to the Form S-1 to understand the financial impact of Ms. Burstein's departure.
- Review the press release attached as Exhibit 99.1 for specific details on the Audit Committee investigation findings.
- Monitor upcoming filings for updates on the review of previously issued financial statements and internal controls.
- Confirm the status of the atherectomy trial and the implications of the shelf life change on inventory and revenue recognition.